Your browser doesn't support javascript.
loading
The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer.
Lonneux M; Borbath I; Berlière M; Kirkove C; Pauwels S.
Afiliación
  • Lonneux M; PET Laboratory, Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
Clin Positron Imaging ; 3(2): 45-49, 2000 Mar.
Article en En | MEDLINE | ID: mdl-10838399
Purpose: To study the role of positron emission tomography 18F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.Procedures: Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.Results: PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.Conclusion: Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies Idioma: En Revista: Clin Positron Imaging Año: 2000 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies Idioma: En Revista: Clin Positron Imaging Año: 2000 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos